Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes.

Chimeric papillomavirus (PV) virus-like particles (VLPs) based on the bovine papillomavirus type 1 (BPV-1) L1 protein were constructed by replacing the 23-carboxyl-terminal amino acids of the BPV1 major protein L1 with an artificial "polytope" minigene, containing known CTL epitopes of human PV16 E7 protein, HIV IIIB gp120 P18, Nef, and reverse transcriptase (RT) proteins, and an HPV16 E7 linear B epitope. The CTL epitopes were restricted by three different MHC class I alleles (H-2(b), H-2(d), HLA-A*0201). The chimeric L1 protein assembled into VLPs when expressed in SF-9 cells by recombinant baculovirus. After immunization of mice with polytope VLPs in the absence of adjuvant, serum antibodies were detected which reacted with both polytope VLPs and wild-type BPV1L1 VLPs, in addition to the HPV16E7 linear B cell epitope. CTL precursors specific for the HPV16 E7, HIV P18, and RT CTL epitopes were also detected in the spleen of immunized mice. Polytope VLPs can thus deliver multiple B and T epitopes as immunogens to the MHC class I and class II pathways, extending the utility of VLPs as self-adjuvanting immunogen delivery systems.

[1]  I. Frazer,et al.  HPV6b virus like particles are potent immunogens without adjuvant in man. , 2000, Vaccine.

[2]  R. Roden,et al.  Mucosal but Not Parenteral Immunization with Purified Human Papillomavirus Type 16 Virus-Like Particles Induces Neutralizing Titers of Antibodies throughout the Estrous Cycle of Mice , 1999, Journal of Virology.

[3]  F. Lemonnier,et al.  An HLA-A2 polyepitope vaccine for melanoma immunotherapy. , 1999, Journal of immunology.

[4]  J. Gardner,et al.  Immunogenicity of a Human Immunodeficiency Virus (HIV) Polytope Vaccine Containing Multiple HLA A2 HIV CD8+ Cytotoxic T-Cell Epitopes , 1999, Journal of Virology.

[5]  A. Benner,et al.  Immune response to human papillomavirus 16 L1E7 chimeric virus‐like particles: Induction of cytotoxic T cells and specific tumor protection , 1999, International journal of cancer.

[6]  I. Frazer,et al.  Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice. , 1998, Virology.

[7]  Fernando Rodriguez,et al.  DNA Immunization with Minigenes: Low Frequency of Memory Cytotoxic T Lymphocytes and Inefficient Antiviral Protection Are Rectified by Ubiquitination , 1998, Journal of Virology.

[8]  G. Fernando,et al.  Vaccine‐Induced Th1‐Type Responses are Dominant over Th2‐Type Responses in the Short Term whereas Pre‐existing Th2 Responses are Dominant in the Longer Term , 1998, Scandinavian journal of immunology.

[9]  I. Frazer,et al.  Type specific and genotype cross reactive B epitopes of the L1 protein of HPV16 defined by a panel of monoclonal antibodies. , 1998, Virology.

[10]  D. Lowy,et al.  Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. Moss,et al.  Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination. , 1998, Journal of immunology.

[12]  A. McMichael,et al.  DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. , 1998, Vaccine.

[13]  I. Frazer,et al.  Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. , 1998, Virology.

[14]  A. Hill,et al.  A protein particle vaccine containing multiple malaria epitopes , 1997, Nature Biotechnology.

[15]  K. Jansen,et al.  Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. , 1997, The Journal of infectious diseases.

[16]  A. Suhrbier,et al.  Multi‐epitope DNA vaccines , 1997, Immunology and cell biology.

[17]  C. Leclerc,et al.  Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Whitton,et al.  A multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and Th epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen , 1997, Journal of virology.

[19]  I. Frazer,et al.  Identification of the alpha6 integrin as a candidate receptor for papillomaviruses , 1997, Journal of virology.

[20]  L. Gissmann,et al.  Carboxyl terminus of bovine papillomavirus type-1 L1 protein is not required for capsid formation. , 1996, Virology.

[21]  D. Lowy,et al.  In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype , 1996, Journal of virology.

[22]  X. Mo,et al.  Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. , 1996, Journal of immunology.

[23]  D. Lowy,et al.  Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. , 1996, Virology.

[24]  N. Christensen,et al.  Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus , 1996, Journal of virology.

[25]  I. Frazer,et al.  Epithelial cells display separate receptors for papillomavirus VLPs and for soluble L1 capsid protein. , 1996, Virology.

[26]  H. Zentgraf,et al.  Early phase in the infection of cultured cells with papillomavirus virions. , 1995, Virology.

[27]  S. H. van der Burg,et al.  Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16‐induced tumors , 1995, European journal of immunology.

[28]  D. Lowy,et al.  Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor , 1995, Journal of virology.

[29]  R. Tindle,et al.  A vaccine conjugate of ‘ISCAR’ immunocarrier and peptide epitopes of the E7 cervical cancer‐associated protein of human papillomavirus type 16 elicits specific Th1‐ and Th2‐type responses in immunized mice in the absence of oil‐based adjuvants , 1995, Clinical and experimental immunology.

[30]  D. McManus,et al.  Antibodies to Schistosoma japonicum (Asian bloodfluke) paramyosin induced by nucleic acid vaccination. , 1995, Biochemical and biophysical research communications.

[31]  E. Paoletti,et al.  Poxvirus‐based vaccine candidates for cancer, AIDS, and other infectious diseases , 1995, Journal of leukocyte biology.

[32]  R. Ahmed,et al.  Recombinant Listeria monocytogenes as a live vaccine vehicle for the induction of protective anti-viral cell-mediated immunity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[33]  H. Zentgraf,et al.  Papillomavirus capsid binding and uptake by cells from different tissues and species , 1995, Journal of virology.

[34]  D. Moss,et al.  Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720) , 1995, Journal of virology.

[35]  G. Dougan,et al.  Chimeric hepatitis B core antigen particles containing B- and Th-epitopes of human papillomavirus type 16 E7 protein induce specific antibody and T-helper responses in immunised mice. , 1994, Virology.

[36]  M. Feltkamp,et al.  Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells , 1993, European journal of immunology.

[37]  A. Kingsman,et al.  Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion , 1993, Journal of virology.

[38]  I. Frazer,et al.  Identification of the nuclear localization signal of human papillomavirus type 16 L1 protein. , 1991, Virology.

[39]  I. Frazer,et al.  Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. , 1991, Virology.

[40]  R. Ahmed,et al.  Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus. I. Generation and recognition of virus strains and H-2b mutants. , 1984, Journal of immunology.

[41]  A. McMichael,et al.  Cytotoxic T-cell immunity to influenza. , 1983, The New England journal of medicine.

[42]  L. Gissmann,et al.  Chimeric papillomavirus-like particles. , 1997, Virology.

[43]  A. Vitiello,et al.  Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. , 1995, The Journal of clinical investigation.

[44]  P. Tiollais,et al.  Recombinant hepatitis B surface antigen as a carrier of human immunodeficiency virus epitopes. , 1993, Research in virology.

[45]  M. Woodruff,et al.  Immune Response , 1969, Nature.